Invitation to submit Phase II contract Qoolabs Inc. 75N93023C00035
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is requesting approval to invite Qoolabs Inc. to submit a Phase II contract proposal for generating and validating research reagents used in unique immune models that support studies of health and disease. The forecast, a new requirement under a Total Small Business set-aside in NAICS 541715, builds on Qoolabs' Phase I contract, under which the firm successfully generated and validated reagents for these models, and it expands that work to produce additional reagents for biomedical research. The estimated solicitation release date is October 1, 2026, and the estimated award date is June 1, 2027.
The estimated award value range is $1.5 million to $3.0 million. Points of contact are Stacy Ferguson, National Institute of Allergy and Infectious Diseases (fergusonst@niaid.nih.gov), and Callie Prassinos, Contracting Officer, NIH (callie.prassinos@nih.gov, +1 240-669-5155).
Forecast text
This PCAIS entry is to request that Qoolabs Inc. be invited to submit a Phase II contract proposal. This contractor provided significant benefit to the government in their prior Phase I contract by successfully generating and validating reagents needed for unique immune models. The Phase II invitation will be an expansion of these activities including generation of more unique reagents needed in the biomedical field for studying health and diseases.
Statement of impact: If this PCAIS entry is not approved, this will reduce the ability of the government to invest in the generation of reagents that are needed to conduct research using unique immune models that are important for studying health and disease, by not allowing a contractor with the capacity to generate the reagents the opportunity to submit a contract proposal for consideration.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast